A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence

被引：0
|
作者：
Dignass, A. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Kelly, O. [4 ]
Rahman, M. [5 ]
Lobaton, T. [6 ]
Addison, J. [7 ]
机构：
[1] Goethe Univ, Agaples Markus Hosp, Dept Med 1, Frankfurt, Germany
[2] Univ Autonoma Madrid UAM, Hosp Univ La Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Madrid, Spain
[3] Fdn Casa Sollievo Sofferenza, Div Gastroenterol, IRCCS San Giovanni Rotondo, Puglia, Italy
[4] Connolly Hosp, Dept Gastroenterol, Dublin, Ireland
[5] Surrey & Sussex Healthcare NHS Trust, Dept Gastroenterol, Surrey, England
[6] Ghent Univ Hosp, Dept Internal Med & Pediat, Dept Gastroenterol, Ghent, Belgium
[7] Biogen Idec Ltd, Clin Res, Maidenhead, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P431
引用
收藏
页码：558 / 559
页数：2
相关论文
共 46 条
  • [41] Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study
    He, Meng-Wen
    Cui, Li
    Chen, Dan-Dan
    Zhao, Yun
    Luo, Wen-Zhao
    Jia, Yun-Fei
    Zhou, Jie
    He, Qing-Juan
    Dai, Ying
    Zhang, Wei-Hua
    Yu, Zhao-Xia
    Wang, Wen-Chang
    Guo, Chang
    Fu, Yi-Ming
    Yang, Wu-Cai
    Li, Xu-Yang
    Guo, Yi-Fan
    Wang, Chun-Yan
    Wang, Jian-Jun
    Li, Ping
    Qiao, Bing
    Ji, Dong
    Li, Zhong-Bin
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (03)
  • [42] SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY
    Schmalzing, M.
    Askari, A.
    Sheeran, T.
    Walsh, D.
    De Toro Santos, J.
    Vazquez Perez-Coleman, J. C.
    Both, C.
    Furlan, F.
    Hachaichi, S.
    Kellner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 540 - 540
  • [43] SHARP EARLY DECLINES IN THE LEVELS OF ALANINE AMINOTRANSFERASE (ALT) AND HEPATITIS B SURFACE ANTIGEN (HBsAg) BUT ELEVATED LIPID LEVELS IN CHRONIC HEPATITIS B PATIENTS (CHB) SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF): 48-WEEK RESULTS FROM A REAL-WORLD PROSPECTIVE COHORT STUDY
    Bi, Yanhua
    Gu, Yurong
    Li, Jing
    Huang, Yuehua
    HEPATOLOGY, 2021, 74 : 495A - 496A
  • [44] Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naive Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
    Askari, Ayman
    Schmalzing, Marc
    Jeka, Slawomir
    Santos, Javier De Toro
    Collantes-Estevez, Eduardo
    Furlan, Fabricio
    Hachaichi, Sohaib
    Kellner, Herbert
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1509 - 1511
  • [45] RETRACTED: An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retracted Article)
    Bokemeyer, B.
    Hlavaty, T.
    Allez, M.
    Selema, P.
    Moosavi, S.
    Cadatal, M. J.
    Fowler, H.
    Cheung, R.
    Lukas, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S410 - S410
  • [46] RETRACTION: An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)
    Bokemeyer, B.
    Hlavaty, T.
    Allez, M.
    Selema, P.
    Moosavi, S.
    Cadatal, M. J.
    Fowler, H.
    Cheung, R.
    Lukas, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (03): : 428 - 428
12345